Regeneron Pharmaceuticals Given New $329.00 Price Target at Goldman Sachs Group Inc. (REGN)
Analysts at Goldman Sachs Group Inc. increased their target price on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $298.00 to $329.00 in a research report issued to clients and investors on Wednesday, AR Network reports. Goldman Sachs Group Inc.’s price objective indicates a potential upside of 6.41% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at TheStreet reiterated a “buy” rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note to investors on Monday. Separately, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $286.00 to $293.00 in a research note to investors on Friday, September 13th. They now have an “outperform” rating on the stock. Finally, analysts at Lazard Capital Markets raised their price target on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $298.00 to $325.00 in a research note to investors on Friday, September 13th. They now have a “buy” rating on the stock.
One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $263.78.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 4.23% on Wednesday, hitting $309.174. The stock had a trading volume of 1,263,721 shares. Regeneron Pharmaceuticals has a one year low of $136.13 and a one year high of $298.43. The stock’s 50-day moving average is $257.2 and its 200-day moving average is $234.0. The company has a market cap of $30.206 billion and a price-to-earnings ratio of 39.22.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.81. The company had revenue of $458.00 million for the quarter, compared to the consensus estimate of $470.63 million. During the same quarter in the previous year, the company posted $0.90 earnings per share. The company’s revenue for the quarter was up 50.5% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $3.49 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 5,000 shares of the stock on the open market in a transaction dated Monday, September 9th. The stock was sold at an average price of $275.47, for a total value of $1,377,350.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.